Federated Hermes Inc. Sells 755,840 Shares of Sanofi (NASDAQ:SNY)

Federated Hermes Inc. reduced its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 30.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,717,320 shares of the company's stock after selling 755,840 shares during the quarter. Federated Hermes Inc. owned about 0.07% of Sanofi worth $85,402,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership boosted its stake in shares of Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company's stock worth $172,611,000 after acquiring an additional 2,468,271 shares in the last quarter. Morgan Stanley raised its holdings in Sanofi by 19.3% during the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company's stock valued at $374,513,000 after buying an additional 1,251,199 shares in the last quarter. Perceptive Advisors LLC bought a new position in Sanofi during the first quarter valued at about $41,800,000. Envestnet Asset Management Inc. raised its holdings in Sanofi by 29.8% during the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company's stock valued at $152,279,000 after buying an additional 651,756 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Sanofi by 24.2% during the second quarter. Goldman Sachs Group Inc. now owns 2,643,615 shares of the company's stock valued at $132,260,000 after buying an additional 515,245 shares in the last quarter. 10.04% of the stock is owned by institutional investors.

Sanofi Price Performance

NASDAQ SNY traded up $0.91 during trading on Friday, reaching $46.30. 3,272,044 shares of the company traded hands, compared to its average volume of 1,915,780. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The stock's 50 day moving average price is $47.52 and its two-hundred day moving average price is $48.62. The company has a market cap of $117.12 billion, a price-to-earnings ratio of 19.62, a P/E/G ratio of 1.72 and a beta of 0.61. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. As a group, analysts anticipate that Sanofi will post 4.15 EPS for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be given a $1.478 dividend. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.38. Sanofi's payout ratio is 58.47%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SNY. Morgan Stanley began coverage on Sanofi in a research note on Tuesday, January 23rd. They issued an "equal weight" rating and a $55.00 price objective on the stock. StockNews.com lowered Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, February 27th. Finally, TheStreet lowered Sanofi from a "b" rating to a "c" rating in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.